Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $304K rose 24.6% year over year, behind the +64.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 42.1% from the prior quarter. Over 3 fiscal years it compounded at +62.8% a year.

Context

  • Stock-based compensation amounted to 3.4% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +24.6% toward the trailing-twelve-month pace of +64.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$304K-42.1% QoQ
Last fiscal yearDec 2025
$1.74M+62.1% YoY
LTMMar 2026
$1.8M+64.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.6%——
1 year+62.1%——
3-year CAGR+62.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
1.74M USD
Year-over-year change
+62.1%
4-year CAGR
+88.0%

Stock-Based Compensation vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +64.7% is the 3rd highest of 8, against a peer median of -10.1%.
  • Stock-based compensation amounts to 3.5% of revenue for CPH.TO, versus a peer median of 1.7%.
CPH.TO Competitors
Stock-Based Compensation for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$7.29M CAD-36.7%-24.4%2.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.23M USD+54.8%+18.6%14.1%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$6.84M CAD+189.7%+62.6%1.3%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$5.06M CAD+220.3%-44.8%1.6%
TSND.TOTerrAscend Corp.LTM Mar 2026$4.38M USD-55.0%-25.6%1.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$2.48M CAD-10.1%+21.0%89.8%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$1.8M USD+64.7%+62.8%3.5%
Peer median (excluding CPH.TO) —-10.1%-2.9%1.7%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.76M26.64M20.38M11.55M27.33M
Depreciation & Amortization701K989K1.23M4.02M7.23M
Deferred Income Tax(114K)(14.31M)(2.74M)(8.64M)(10.36M)
Stock-Based Compensation139K403K1.19M1.07M1.74M
Change in Working Capital4.68M(3.03M)(3.28M)8.95M5.32M
Accounts Receivables2.56M(144K)1.71M(8.77M)2.7M
Inventory(758K)(502K)(830K)3.6M(2.44M)
Accounts Payables(1.23M)(1.45M)532K1.28M527.07K
Other Working Capital4.11M(940K)(4.69M)12.85M4.53M
Other Non-Cash Items652K(109K)(788K)2.6M(1.01M)
Operating Cash Flow13.81M10.58M16M19.55M30.25M
Capital Expenditures0(81K)(144K)(44K)(28.49K)
Acquisitions (Net)0000132.28K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(123K)(80M)0
Investing Cash Flow0(81K)(144K)(80.04M)(72.24K)
Debt Repayment(828K)(56K)(111K)39.79M(35.61M)
Common Stock Issued0000218.76K
Common Stock Repurchased(1.72M)(1.99M)(5.56M)(176K)(5.48M)
Dividends Paid00000
Other Financing Activities75K132K426K(317K)(311.36K)
Financing Cash Flow(2.47M)(1.91M)(5.24M)39.3M(41.18M)
Effect of Forex Changes62K(292K)378K(786K)(194.92K)
Net Change in Cash11.41M8.29M10.99M(21.99M)(11.2M)
Free Cash Flow13.81M10.49M15.98M19.5M30.22M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.